Parkinson Disease 16

Also Known As:

PARK16

Networked: 17 relevant articles (0 outcomes, 2 trials/studies)

Disease Context: Research Results

Nervous System Diseases: 14178
- Neurodegenerative Diseases: 42472
  - Synucleinopathies: 2123
    - Parkinson Disease: 59384
      - Parkinson Disease 16: 17
- Central Nervous System Diseases: 4213
  - Brain Diseases: 15694
    - Basal Ganglia Diseases: 346
      - Parkinsonian Disorders: 9203
        Parkinson Disease: 59384
        Parkinson Disease 16: 17
  - Movement Disorders: 4634
    - Parkinsonian Disorders: 9203
      - Parkinson Disease: 59384
        Parkinson Disease 16: 17

Related Diseases

1.	Psychotic Disorders (Schizoaffective Disorder)
2.	Alcoholism (Alcohol Abuse)
3.	Parkinson Disease (Parkinson's Disease)
4.	Parkinson Disease 16

Experts

1.	Huang, Zini: 1 article (09/2022)
2.	Li, Binbin: 1 article (09/2022)
3.	Li, Jiaxin: 1 article (09/2022)
4.	Shu, Li: 1 article (09/2022)
5.	Yi, Minhan: 1 article (09/2022)
6.	Yin, Shujuan: 1 article (09/2022)
7.	Zhang, Ying: 1 article (09/2022)
8.	Zhang, Yuan: 1 article (09/2022)
9.	Chen, Gang: 1 article (03/2021)
10.	Gao, Heng: 1 article (03/2021)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Parkinson Disease 16:

1.	HLA-DRB5 Chains (HLA DRB5)IBA 08/03/2011 - "The majority of studies have confirmed the association of the previously identified genetic risk factors, SNCA and MAPT, and two studies have identified three new PD susceptibility loci/genes (PARK16, BST1 and HLA-DRB5). "
2.	LipopolysaccharidesIBA 01/01/2021 - "Since VT is the sum of the ligand-specific distribution volume (VS) and the nondisplaceable-binding distribution volume (VND), differences in VND across subjects and groups will have an impact on VTMethods: Here, we used a recently developed method for simultaneous estimation of VND (SIME) to disentangle contributions from VND and VS Data from 4 previously published 11C-PBR28 PET studies were included: before and after a lipopolysaccharide challenge (8 subjects), in alcohol use disorder (14 patients, 15 controls), in first-episode psychosis (16 patients, 16 controls), and in Parkinson disease (16 patients, 16 controls). "
3.	LigandsIBA 01/01/2021 - "Since VT is the sum of the ligand-specific distribution volume (VS) and the nondisplaceable-binding distribution volume (VND), differences in VND across subjects and groups will have an impact on VTMethods: Here, we used a recently developed method for simultaneous estimation of VND (SIME) to disentangle contributions from VND and VS Data from 4 previously published 11C-PBR28 PET studies were included: before and after a lipopolysaccharide challenge (8 subjects), in alcohol use disorder (14 patients, 15 controls), in first-episode psychosis (16 patients, 16 controls), and in Parkinson disease (16 patients, 16 controls). "
4.	(methyl- (11)C)N- acetyl- N- (2- methoxybenzyl)- 2- phenoxy- 5- pyridinamineIBA 01/01/2021 - "Since VT is the sum of the ligand-specific distribution volume (VS) and the nondisplaceable-binding distribution volume (VND), differences in VND across subjects and groups will have an impact on VTMethods: Here, we used a recently developed method for simultaneous estimation of VND (SIME) to disentangle contributions from VND and VS Data from 4 previously published 11C-PBR28 PET studies were included: before and after a lipopolysaccharide challenge (8 subjects), in alcohol use disorder (14 patients, 15 controls), in first-episode psychosis (16 patients, 16 controls), and in Parkinson disease (16 patients, 16 controls). "
5.	Brain-Derived Neurotrophic Factor (BDNF)IBA 09/01/2022 - "Consequently, SLC6A4/5-HTT HTTLPR, BDNF rs56164415, FGF20 rs1721100, PARK16 rs823128, rs823156, rs947211, APOE e2, A2M rs669, RIT2 rs12456492, MAPT intron 9 H1H2, and STH rs62063857 variants were statistically associated with PD risk while researched variants in COMT, DBH, MAO, DAT/SLC6A3, DRD2, GRIN2B, GSK3β, ATP13A2, LINGO1, PICALM, and GRN were not related to PD risk. " 06/13/2023 - "Results: in particular, polymorphisms in genes related to the serotoninergic pathway (sodium-dependent serotonin transporter gene, SLC6A4, tryptophan hydrolase-2 gene, TPH2), dopamine metabolism and neurotransmission (dopamine receptor D3 gene, DRD3, aldehyde dehydrogenase 2 gene, ALDH2), neurotrophic factors (brain-derived neurotrophic factor gene, BDNF), endocannabinoid system (cannabinoid receptor gene, CNR1), circadian rhythm (thyrotroph embryonic factor gene, TEF), the sodium-dependent neutral amino acid transporter B(0)AT2 gene, SLC6A15), and PARK16 genetic locus were detected as altering susceptibility to depression among PD patients. "
6.	Phosphotransferases (Kinase)IBA 07/01/2017 - "Encoded by a gene within the PARK16 locus, RAB7L1 interacts with Leucine-rich repeat kinase 2 (LRRK2) to act in intracellular transport processes that are likely important for neuronal survival and function. " 01/01/2012 - "Numerous GWAS linked loci including BST1 (bone marrow stromal cell antigen 1), PARK16 (parkinson disease 16 susceptibility), GAK (cyclin G associated kinase), and HLA (human leukocyte antigen) have also been identified. "
7.	MagnesiumIBA 01/01/2016 - "First, the gene encoding magnesium transporter SLC41A1 is, among others, a candidate for the causative gene in the PARK16 locus where variation is associated with risk for idiopathic Parkinsonian disease. " 01/01/2013 - "Interestingly, gene SLC41A1 located in the novel PD locus PARK16 has recently been identified as being a Na⁺/Mg²⁺ exchanger (NME, Mg²⁺ efflux system), a key component of cellular magnesium homeostasis. "
8.	DNA (Deoxyribonucleic Acid)IBA 04/10/2015 - "Polymerase chain reaction-restriction fragment length polymorphism analysis and DNA sequencing were used to detect the rs947211 and rs823144 polymorphism in the PARK16 gene between the Xinjiang Uygur and Han populations. " 11/01/2011 - "We performed direct DNA sequencing of the RAB7L1 and SLC41A1 genes within the PARK16 locus in 205 Chinese Parkinson's disease (PD) patients. "
9.	Apolipoproteins E (ApoE)IBA 11/01/2013 - "We selected 25 single nucleotide polymorphisms (SNPs) in 9 genes (ABCA7, APOE, BST1, CLU, CR1, LRRK2, PARK16, PICALM, and SNCA) that were genotyped in 1036 PD case patients and 1208 controls. " 09/01/2022 - "Consequently, SLC6A4/5-HTT HTTLPR, BDNF rs56164415, FGF20 rs1721100, PARK16 rs823128, rs823156, rs947211, APOE e2, A2M rs669, RIT2 rs12456492, MAPT intron 9 H1H2, and STH rs62063857 variants were statistically associated with PD risk while researched variants in COMT, DBH, MAO, DAT/SLC6A3, DRD2, GRIN2B, GSK3β, ATP13A2, LINGO1, PICALM, and GRN were not related to PD risk. "
10.	EndocannabinoidsIBA 06/13/2023 - "Results: in particular, polymorphisms in genes related to the serotoninergic pathway (sodium-dependent serotonin transporter gene, SLC6A4, tryptophan hydrolase-2 gene, TPH2), dopamine metabolism and neurotransmission (dopamine receptor D3 gene, DRD3, aldehyde dehydrogenase 2 gene, ALDH2), neurotrophic factors (brain-derived neurotrophic factor gene, BDNF), endocannabinoid system (cannabinoid receptor gene, CNR1), circadian rhythm (thyrotroph embryonic factor gene, TEF), the sodium-dependent neutral amino acid transporter B(0)AT2 gene, SLC6A15), and PARK16 genetic locus were detected as altering susceptibility to depression among PD patients. "